Related Experiment Video
Updated: Jun 11, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN
Michael J Bloch1,2, Ajay J Kirtane3, Michel Azizi4,5,6
1Department of Medicine, University of Nevada School of Medicine, Vascular Care, Reno, NV, USA. michael@bluesprucemed.com.
Abstract:
Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.
More Related Videos
06:38Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Imaging Studies II: Ultrasonography
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension IV: Drug Therapy and Lifestyle Modifications
Continuous Renal Replacement Therapy
Heart Failure V: Medical Management